Grupo de Investigación en cáncer colorrectal y nuevos desarrollos terapéuticos en tumores sólidos

Área de Oncología

Nuestro grupo tiene como objetivo mejorar la vida del paciente mediante el desarrollo de nuevos métodos diagnósticos y terapéuticos. Además de este objetivo principal, pretendemos implementar estrategias que faciliten el desarrollo de la medicina de precisión en tumores sólidos con enfoques terapéuticos innovadores y brindar conocimientos sobre cómo abordar la medicina de precisión en el cáncer colorrectal y gástrico desde diferentes puntos como la clasificación molecular, el uso de biomarcadores predictivos y nuevos enfoques terapéuticos
Coordinador
Dr. Andrés Cervantes Ruipérez
andres.cervantes@uv.es
INVESTIGADORES
R4 Senior

Andrés Cervantes Ruipérez    

R3 Consolidado

Gerardo López Rodas
Desamparados Roda Pérez

R2 Novel / Emergente

Amelia Insa Mollá
Francisco Gimeno Valiente
Jose A. Pérez Fidalgo
Josefa Castillo Aliaga
Mª Carolina Martínez Ciarpaglini
Maider Ibarrola Villava
Susana Roselló Keranen
Valentina Gambardella
Noelia Tarazona Llavero

Tania Fleitas Kanonnikoff

R1 Predoctoral

Federica Papaccio
Fernanda Gutiérrez Bravo
Gema Bruixola Campos
Jorge Martín Arana
José Francisco González Muñoz
Manuel Cabeza Segura
Marisol Huerta Álvaro
Paloma Martín Martorell
Roberto Tebar Martínez

STAFF
Colaborador/a

Clara Alfaro Cervelló

Enfermero/a

Ana Ruiz Quílez
Celia Martínez Ridaura
Cristina Jordá Guerola
Estela Contel Martín
Inma Blasco Blasco
Luna Porta Campos
Verónica García Oliver

Técnico/a

Alba Viala Monleón
Ana Ferrer Martínez
Bea López Montero
Blanca García Micó
Cristina Mongort Sanchis
Helen Manzaneda López
Ignacio Castaño López
Laura Olivares Ordóñez
Mª Pilar Natividad López
Zahara Garzón Lloria

Apoyo

Ana Vercher Grau
Enrique Castelló Moreno
Gabriela Pérez Garity

Publicaciones

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cáncer. Schmid P, Sablin M, Bergh J, Im S, Lu Y, Martinez N, Neven P, Lee K, Morales S, Perez-Fidalgo J, Adamson D, Goncalves A, Prat A, Jerusalem G, Schlieker L, Espadero R, Bogenrieder T, Huang D, Crown J, Cortes J. Breast Cancer Research. 2021 Jan 15;23(1):8. doi: 10.1186/s13058-020-01382-8. PMID: 33451345Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia J, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. ESMO Open. 2021 Jul 24;6(5):100237. doi: 10.1016/j.esmoop.2021.100237. PMID: 34411971

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. ESMO open. 2021 Apr 19;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. PMID: 33887690

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Laza-Briviesca R, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo M, Huidobro G, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno J, Cobo M, Vivanco G, Del Barco E, Caro R, Vinolas N, Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarin C, Garcia-Grande A, Haymaker C, Wistuba I, Romero A, Franco F, Provencio M. Clinical and Translational Medicine. 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491. PMID: 34323406

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994. PMID: 33673558

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, Garcia-Grande A, Romero A, Franco F, Provencio M. Journal for ImmunoTherapy of Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804. PMID: 34446577

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Lambertini M, Ceppi M, Hamy A, Caron O, Poorvu P, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Perez-Fidalgo J, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz M, Villarreal-Garza C, Dieci M, Clatot F, Duhoux F, Graffeo R, Teixeira L, Cordoba O, Sonnenblick A, Ferreira A, Partridge A, Di Meglio A, Saule C, Peccatori F, Bruzzone M, t’Kint de Roodenbeke M, Ameye L, Balmana J, Del Mastro L, Azim H. NPJ breast cancer. 2021 Feb 12;7(1):16. doi: 10.1038/s41523-021-00224-w. PMID: 33579978

Clinicians’ attitude to doublet plus Anti-EGFR versus triplet plus bevacizumab as first-line treatment in left-sided RAS and BRAF wild-type metastatic colorectal cancer patients: a multicenter, «real-life», case-control study. Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, Salvatore L, Tortora G, Ribelli M, Nigro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, Dell’Aquila E, Claudia F, Lombardi P, Keranen S, Aimar G, Depetris I, Giampieri R, Morelli C, De Tursi M, Tinari N, Di Pietro F, De Galitiis F, Zanaletti N, Troiani T, Vitale P, Garajova I, Ghidini M, Spinelli G, Zoratto F, Roberto M, Ierino D, Petrillo A, D’Orazio C, Ficorella C, Cortellini A. Clinical Colorectal Cancer. 2021 Jul 18;S1533-0028(21)00068-2. doi: 10.1016/j.clcc.2021.07.003. PMID: 34380594

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Romero A, Jantus-Lewintre E, Garcia-Pelaez B, Royuela A, Insa A, Cruz P, Collazo A, Altozano J, Vidal O, Diz P, Cobo M, Hernandez B, Estevez S, Benitez G, Guirado M, Majem M, Bernabe R, Ortega A, Blasco A, Bosch-Barrera J, Jurado J, Gonzalez J, Viteri S, Giron C, Massuti B, Martin A, Rodriguez-Festa A, Calabuig-Farinas S, Molina-Vila M, Provencio M. Molecular Oncology. 2021 Jan;15(1):43-56. doi: 10.1002/1878-0261.12832. PMID: 33107189

Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. Marti-Aguado D, Rodriguez-Ortega A, Mestre-Alagarda C, Bauza M, Valero-Perez E, Alfaro-Cervello C, Benlloch S, Perez-Rojas J, Ferrandez A, Alemany-Monraval P, Escudero-Garcia D, Monton C, Aguilera V, Alberich-Bayarri A, Serra M, Marti-Bonmati L. Alimentary Pharmacology & Therapeutics. 2021 Jan;53(1):160-171. doi: 10.1111/apt.16100. PMID: 32981113

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cáncer. Kaminska K, Akrap N, Staaf J, Alves C, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg A, Perez-Fidalgo A, Ditzel H, Bosch A, Honeth G. Breast Cancer Research. 2021 Feb 18;23(1):26. doi: 10.1186/s13058-021-01402-1. PMID: 33602273

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Riudavets M, Bosch-Barrera J, Cabezon-Gutierrez L, Tain P, Hernandez A, Alonso M, Blanco R, Galvez E, Insa A, Mielgo X, Moran T, Ponce S, Roa D, Sanchez J, Majem M. Clinical & Translational Oncology. 2021 Jul 22. doi: 10.1007/s12094-021-02661-2. PMID: 34292495

Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: 10.3390/cancers13061433. PMID: 33801071

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Annals of Oncology. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34090547

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO open. 2021 Jun;6(3):100130. doi: 10.1016/j.esmoop.2021.100130. PMID: 34144776

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. Cancer Immunology Immunotherapy. 2021 Jul 3. doi: 10.1007/s00262-021-02973-w. PMID: 34216247

Folliculotropic mycosis fungoides with flexural eruptive cysts and comedones in a 14-year-old boy. Roca-Gines J, Alfaro-Cervello C, Sanchez-Arraez J, Torres-Navarro I, Navarro-Mira MA, Monteagudo C, Botella-Estrada R. American Journal of Dermatopathology. 2021 May 11. doi: 10.1097/DAD.0000000000001958. PMID: 33989213

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice M, Giovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: 10.1016/j.ccell.2021.03.004. PMID: 33798472

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). Jimenez-Labaig P, Pacheco-Barcia V, Cebria A, Galvez F, Obispo B, Paez D, Quilez A, Quintanar T, Ramchandani A, Remon J, Rogado J, Sanchez D, Sanchez-Canovas M, Sanz-Garcia E, Sesma A, Tarazona N, Cotes A, Gonzalez E, Bosch-Barrera J, Fernandez A, Felip E, Vera R, Rodriguez-Lescure A, Elez E. ESMO Open. 2021 Jul 26;6(4):100215. doi: 10.1016/j.esmoop.2021.100215. PMID: 34325108

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. Esmo Open. 2021 Jan 4;6(1):100009. doi: 10.1016/j.esmoop.2020.100009. PMID: 33399075

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. Esmo Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phaseII trial (ROLANDO study). Perez-Fidalgo J, Cortes A, Guerra E, Garcia Y, Iglesias M, Bohn Sarmiento U, Calvo Garcia E, Manso Sanchez L, Santaballa A, Oaknin A, Redondo A, Rubio M, Gonzalez-Martin A. ESMO Open. 2021 Jul 27;6(4):100212. doi: 10.1016/j.esmoop.2021.100212. PMID: 34329939

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. Pellino G, Garcia-Granero E, Cervantes A. European Journal of Surgical Oncology. 2021 Jun 29;S0748-7983(21)00596-5. doi: 10.1016/j.ejso.2021.06.031. PMID: 34217579

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Jhaveri K, Chang M, Juric D, Saura C, Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C, Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Clinical Cancer Research. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. PMID: 33148674

Postoperative ctDNA monitoring: a canary in a coalmine. Lumish M, Tarazona N, Janjigian Y. Annals of oncology. 2021 Jan 20;S0923-7534(21)00013-2. doi: 10.1016/j.annonc.2021.01.005. PMID: 33484835

Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo R, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra E, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba I, Romero A, Calvo V, Provencio M. Clinical Cancer Research. 2021 Aug 10;clincanres.1200.2021. doi: 10.1158/1078-0432.CCR-21-1200. PMID: 34376534

Radiomics and radiogenomics in head and neck squamous cell carcinoma: potential contribution to patient management and challenges. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, Monton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. Cancer Treatment Reviews. 2021 Sep;99:102263. doi: 10.1016/j.ctrv.2021.102263. PMID: 34343892

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 May 24;S0923-7534(21)02019-6. doi: 10.1016/j.annonc.2021.05.795. PMID: 34033882

Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory Metastatic Colorectal Cancer (mCRC) patients: a multi-institution real life clinical data. Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosellò S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Clinical Colorectal Cancer. 2021 Jun 10;S1533-0028(21)00052-9. doi: 10.1016/j.clcc.2021.06.002. PMID: 34226142

SEOM clinical guideline in ovarian cancer (2020). Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo J, Varela M, Rubio M, Barretina-Ginesta M, Gonzalez-Martin A. Clinical & translational oncology. 2021 Jan 30. doi: 10.1007/s12094-020-02545-x. PMID: 33515422

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Kranenbarg E, Roodvoets A, Nagtegaal I, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, Capdevila J, Hendriks M, Edhemovic I, Cervantes A, Nilsson P, Glimelius B, van de Velde C, Hospers G, RAPIDO collaborative investigators. Lancet. Oncology. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. PMID: 33301740

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. Pellino G, Alós R, Biondo S, Codina-Cazador A, Enríquez-Navascues J, Espín-Basany E, Roig-Vila J, Cervantes Ruiperez A, Carceller R, Spanish Rectal Cancer Project collaborators. EJSO. 2021 Feb;47(2):276-284. doi: 10.1016/j.ejso.2020.04.056. PMID: 32950316

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Delord J, Argiles G, Fayette J, Wirth L, Kasper S, Siena S, Mesia R, Berardi R, Cervantes Ruiperez A, Dekervel J, Zhao S, Sun Y, Hao H, Tiedt R, Vicente S, Myers A, Siu L. Investigational New Drugs. 2020 Dec;38(6):1774-1783. doi: 10.1007/s10637-020-00928-z. PMID: 32410080A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. Gavila J, De La Haba J, Bermejo De Las Heras B, Rodriguez-Lescure A, Anton A, Ciruelos E, Brunet J, Munoz-Couselo E, Santisteban M, Rodriguez Sanchez C, Santaballa A, Sanchez Rovira P, Garcia Saenz J, Ruiz-Borrego M, Guerrero-Zotano A, Huerta Alvaro M, Cotes-Sanchis A, Lao Romera J, Aguirre E, Cortes J, Llombart-Cussac A. Clinical & Translational Oncology. 2020 Mar;22(3):420-428. doi: 10.1007/s12094-019-02145-4. PMID: 31203575

Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer. Smyth E, Cervantes Ruiperez A. Esmo Open. 2020 Nov;5(6):e001107. doi: 10.1136/esmoopen-2020-001107. PMID: 33208490

Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. Sclafani F, Hulkki Wilson S, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Rosello S, Thomas J, Tait D, Brown G, Oates J, Chau I. International Journal of Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. PMID: 31199501

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. Isakoff S, Tabernero J, Molife L, Soria J, Cervantes Ruiperez A, Vogelzang N, Patel M, Hussain M, Baron A, Argiles G, Conkling R, Sampath D, Maslyar D, Patel P, Chan W, Gendreau S, Musib L, Xu N, Ma H, Lin K, Bendell J. Annals of Oncology. 2020 May;31(5):626-633. doi: 10.1016/j.annonc.2020.02.007. PMID: 32205017

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial. Chibaudel B, Henriques J, Rakez M, Brenner B, Kim Tae Won, Martinez Villacampa M, Gallego Plazas J, Cervantes A, Shim K, Jonker D, Guerin Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, Andre T, de Gramont A. Jama Network Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425. PMID: 33074326

Aurora kinases in ovarian cancer. Perez Fidalgo J, Gambardella V, Pineda Merlo B, Burgues Gasion O, Piñero Sanchez O, Cervantes Ruiperez A. Esmo Open. 2020 Oct;5(5):e000718. doi: 10.1136/esmoopen-2020-000718. PMID: 33087400

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. Pavlidis N, Peccatori F, Aapro M, Rolfo C, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Critical Reviews in Oncology Hematology. 2020 Feb;146:102798. doi: 10.1016/j.critrevonc.2019.07.022. PMID: 31918958

Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Derks S, de Klerk L, Xu X, Fleitas Kanonnikoff T, Liu K, Liu Y, Dietlein F, Margolis C, Chiaravalli A, Da Silva A, Ogino S, Akarca F, Freeman G, Rodig S, Hornick J, VAN Allen E, Li B, Liu S, Thorsson V, Bass A. Annals of Oncology. 2020 Aug;31(8):1011-1020. doi: 10.1016/j.annonc.2020.04.011. PMID: 32387455

Chronological Age Interacts with the Circadian Melatonin Receptor 1B Gene Variation, Determining Fasting Glucose Concentrations in Mediterranean Populations. Additional Analyses on Type-2 Diabetes Risk. Sorli J, Barragan R, Coltell O, Portoles O, Pascual E, Ortega-Azorin C, Gonzalez J, Estruch R, Saiz C, Perez-Fidalgo A, Ordovas J, Corella D. Nutrients. 2020 Oct 29;12(11):3323. doi: 10.3390/nu12113323. PMID: 33138317

Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2020 Apr 17. doi: 10.1007/s13187-020-01744-y. PMID: 32303982

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Garcia Campelo R, Arrieta O, Massuti B, Rodriguez Abreu D, Ortega Granados AL, Majem M, Vicente D, Lianes P, Bosch Barrera J, Insa A, Domine M, Reguart N, Guirado M, Sala MA, Vazquez Estevez S, Bernabe Caro, R, Drozdowskyj A, Verdu A, Karachaliou N, Molina Vila MA, Rosell R. Lung Cancer. 2020 Dec;150:62-69. doi: 10.1016/j.lungcan.2020.09.018. PMID: 33070053

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial (vol 147, pg 75, 2020). van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot Derk JA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:e1. doi: 10.1016/j.radonc.2020.06.006. PMID: 32564889

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot DJA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:75-83. doi: 10.1016/j.radonc.2020.03.011. PMID: 32240909

Computational evaluation and in vitro validation of new Epidermal Growth Factor Receptor inhibitors. Gomez-Ganau S, Castillo Aliaga J, Cervantes Ruiperez A, de Julian Ortiz J, Gozalbes R. Current Topics in Medicinal Chemistry. 2020;20(18):1628-1639. doi: 10.2174/1568026620666200603122726. PMID: 32493189

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. Tarazona Llavero N, Gimeno Valiente F, Gambardella V, Huerta Alvaro M, Roselló Keränen S, Zúñiga Trejos S, Calon A, Carbonell Asins J, Fontana E, Martínez Ciarpaglini M, Eason K, Rentero Garrido P, Fleitas Kanonnikoff T, Papaccio F, Moro Valdezate D, Nyamundanda G, Castillo Aliaga J, Espí Macias A, Sadanandam A, Roda Perez D, Cervantes Ruiperez A. Esmo Open. 2020 Sep;5(5):e000847. doi: 10.1136/esmoopen-2020-000847. PMID: 32967918

Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. Velasco R, Mercadal S, Vidal N, Alana M, Barcelo M, Ibanez-Julia M, Bobillo S, Caldu Agud R, Garcia Molina E, Martinez P, Cacabelos P, Muntanola A, Garcia-Catalan G, Sancho J, Camro I, Lado T, Erro M, Gomez-Vicente L, Salar A, Caballero A, Sole-Rodriguez M, Gallego Perez-Larraya J, Huertas N, Estela J, Baron M, Barbero-Bordallo N, Encuentra M, Dlouhy I, Bruna J, Graus F, Bruixola Campos G, GELTAMO & GENOSEN Grp. Journal of Neuro-Oncology. 2020 Jul;148(3):545-554. doi: 10.1007/s11060-020-03547-z. PMID: 32524392

Easy One-Step Amplification and Labeling Procedure for Copy Number Variation Detection. Blesa Luján S, Olivares Gazquez M, Alic A, Serrano Alcalá A, Lendinez Tortajada V, Gonzalez Albert V, Olivares Ordoñez L, Martinez Hervas S, Juanes Tébar J, Marin P, Real Collado J, Navarro Cubells B, García García A, Chaves Martínez F, Ivorra C. Clinical Chemistry. 2020 Mar 1;66(3):463-473. doi: 10.1093/clinchem/hvaa002. PMID: 32068788

Editorial debate: Challenges we oncologists, working within a universal healthcare system, have to face in these hard times. Cervantes Ruiperez A. Esmo Open. 2020 May;5(3):e000800. doi: 10.1136/esmoopen-2020-000800. PMID: 32366509

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Smyth L, Piha-Paul S, Won H, Schram A, Saura C, Loi S, Lu J, Shapiro G, Juric D, Mayer I, Arteaga C, de la Fuente M, Brufksy A, Spanggaard I, Mau-Sorensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg L, Gonzalez-Farre X, Cervantes Ruiperez A, Bidard F, Gorelick A, Lanman R, Nagy R, Ulaner G, Chandarlapaty S, Jhaveri K, Gavrila E, Zimel C, Selcuklu S, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli L, Dujka M, Lalani A, Bryce R, Baselga J, Taylor B, Solit D, Meric-Bernstam F, Hyman D. Cancer Discovery. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. PMID: 31806627

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review. Samartzis E, Labidi-Galy S, Moschetta M, Uccello M, Kalaitzopoulos D, Perez-Fidalgo J, Boussios S. Annals of Translational Medicine. 2020 Dec;8(24):1712. doi: 10.21037/atm-20-3022a. PMID: 33490224

EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. Gimeno Valiente F, Riffo Campos Á, Ayala Gallego G, Tarazona Llavero N, Gambardella V, Rodriguez F, Huerta Alvaro M, Martínez Ciarpaglini M, Monton Bueno J, Roselló Keränen S, Roda Perez D, Cervantes Ruiperez A, Franco Vera L, Lopez Rodas G, Castillo Aliaga J. Scientific Reports. 2020 Feb 28;10(1):3723. doi: 10.1038/s41598-020-60476-7. PMID: 32111877

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter «SLAVE» Study. Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari M, Salvatore L, Tortora G, Rossini D, Germani M, Boccaccino A, Dell’aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino P, Lombardi P, Roselló Keränen S, Huerta Alvaro M, Zurlo I, Corsi D, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti M, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache S, Porzio G, Ficorella C. Cancers. 2020 May 16;12(5):1259. doi: 10.3390/cancers12051259. PMID: 32429380

How we treat metastatic colorectal cáncer. De Falco V, Napolitano S, Rosello S, Huerta M, Cervantes A, Ciardiello F, Troiani T. Esmo Open. 2020 Aug;4(Suppl 2):e000813. doi: 10.1136/esmoopen-2020-000813. PMID: 32817137

Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. Baguena G, Pellino G, Frasson M, Escrig J, Marinello F, Espí Macias A, Garcia-Granero A, Roselló Keränen S, Cervantes Ruiperez A, Garcia-Granero E. Gastroenterologia y Hepatologia. 2020 Feb;43(2):63-72. doi: 10.1016/j.gastrohep.2019.07.005. PMID: 31918857

In the literature: April 2020. Gambardella V, Roda D, Tarazona N, Cervantes A. Esmo Open. 2020 Apr;5(2):e000749. doi: 10.1136/esmoopen-2020-000749. PMID: 32317263

In the literature: August 2020. Gambardella V, Cejalvo J, Tarazona N, Cervantes A. Esmo Open. 2020 Aug;5(4):e000909. doi: 10.1136/esmoopen-2020-000909. PMID: 32817070

In the literature: December 2019. Gambardella V, Insa A, Cejalvo J, Cervantes A. Esmo Open. 2020 Jan;5(1):e000642. doi: 10.1136/esmoopen-2019-000642. PMID: 31958287

In the literature: February 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. PMID: 32079625

In the literature: June 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. Esmo Open. 2020 Jul;5(4):e000832. doi: 10.1136/esmoopen-2020-000832. PMID: 32641355

In the literature: October 2020. Gambardella V, Bruixola Campos G, Alfaro Cervelló C, Cervantes Ruiperez A. Esmo Open. 2020 Oct;5(5):e001048. doi: 10.1136/esmoopen-2020-001048. PMID: 33037034

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Guo C, Chenard-Poiriet M, Roda D, de Miguel M, Harris S, Candilejo I, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner A, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez J, Minchom A, de Bono J, Banerji U. The Lancet Oncology. 2020 Nov;21(11):1478-1488. doi: 10.1016/S1470-2045(20)30464-2. PMID: 33128873

Intrasinusoidal HHV8-EBV-Positive Large B-Cell Lymphoma With Features of Germinotropic Lymphoproliferative Disorder. Martínez Ciarpaglini M, Valkov A, Hurtado M, Agusti Martinez J, Malave G, Ferrandez Izquierdo A. International Journal of Surgical Pathology. 2020 Oct;28(7):804-811. doi: 10.1177/1066896920921238. PMID: 32423260

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Yoshino T, Pentheroudakis G, Mishima S, Overman M, Yeh K, Baba E, Naito Y, Calvo F, Saxena A, Chen L, Takeda M, Cervantes Ruiperez A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard J. Annals of Oncology. 2020 Jul;31(7):861-872. doi: 10.1016/j.annonc.2020.03.299. PMID: 32272210

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Remon J, Nadal E, Domine M, Ruffinelli J, Garcia Y, Pardo JC, Lopez R, Cilleruelo A, Garcia Campelo R, Martin P, Juan O, Gonzalez Larriba JL, Provencio M, Olmedo E, Ponce S, Cumplido D, Barenys C, Majem M, Massutti B, Rodriguez Abreu D, Porta R, Sala MA, Martinez Kareaga M, Lianes P, Reguart N. Lung Cancer. 2020 Sep;147:83-90. doi: 10.1016/j.lungcan.2020.06.034. PMID: 32682189

Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus. Curigliano G, Banerjee S, Cervantes Ruiperez A, Garassino M, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels J, Michielin O, Peters S, Tabernero J, Douillard J, Pentheroudakis G, all Voting Panel members. Annals of Oncology. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. PMID: 32745693

Melanoma of Unknown Primary: New Perspectives for an Old Story. Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Perez-Fidalgo J, Pavlidis N. Critical reviews in oncology/hematology. 2020 Dec 28;158:103208. doi: 10.1016/j.critrevonc.2020.103208. PMID: 33383207

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Provencio M, Nadal E, Insa A, Garcia-Campelo M, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno J, Cobo M, Vivanco G, Del Barco E, Caro R, Vinolas N, Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Anton C, Parra E, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermudez A. Lancet Oncology. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. PMID: 32979984

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Papaccio F, Rosello S, Huerta M, Gambardella V, Tarazona N, Fleitas T, Roda D, Cervantes A. Cancers. 2020 Dec 3;12(12):E3611. doi: 10.3390/cancers12123611. PMID: 33287114

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A, Alfaro-Cervello C, Jorda E, Garces-Albir M, Roda D, Dorcaratto D, Tarazona N, Torondel S, Guijarro J, Sanchiz V, Gambardella V, Fleitas-Kanonnikoff T, Lluch P, Pascual I, Ferrandez A, Sabater L, Cervantes A. Esmo Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. PMID: 33229503

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

NOTCH signalling in ovarian cancer angiogénesis. Perez-Fidalgo J, Ortega B, Simon S, Samartzis E, Boussios S. Annals of Translational Medicine. 2020 Dec;8(24):1705. doi: 10.21037/atm-20-4497. PMID: 33490217

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

Personalized Medicine: Recent Progress in Cancer Therapy. Gambardella V, Tarazona Llavero N, Cejalvo Andujar J, Lombardi P, Huerta Alvaro M, Roselló Keränen S, Fleitas Kanonnikoff T, Roda Perez D, Cervantes Ruiperez A. Cancers. 2020 Apr 19;12(4):1009. doi: 10.3390/cancers12041009. PMID: 32325878

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cáncer. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. British Journal of Cancer. 2020 Nov;123(11):1590-1598. doi: 10.1038/s41416-020-01041-x. PMID: 32913286

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim J, Carreira S, Roda Perez D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner N, Ruddle R, Raynaud F, Decordova S, Swales K, Finneran L, Hall E, Rugman P, Lindemann J, Foxley A, Lord C, Banerji U, Plummer R, Basu B, Lopez J, Drew Y, de Bono J.Cancer Discovery. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163.PMID: 32532747

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Gambardella V, Fleitas Kanonnikoff T, Tarazona Llavero N, Papaccio F, Huerta Alvaro M, Roselló Keränen S, Gimeno Valiente F, Roda Perez D, Cervantes Ruiperez A. Journal of Clinical Medicine. 2020 Sep 22;9(9):3049. doi: 10.3390/jcm9093049. PMID: 32971757

Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. Lambertini M, Ameye L, Hamy A, Zingarello A, Poorvu P, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Perez Fidalgo J, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz M, Villarreal-Garza C, Dieci M, Clatot F, Berliere M, Graffeo R, Teixeira L, Cordoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge A, Caron O, Saule C, Del Mastro L, Peccatori F, Azim H. Journal of Clinical Oncology. 2020 Sep 10;38(26):3012-3023. doi: 10.1200/JCO.19.02399. PMID: 32673153

Sun exposure and PDZK1 genotype modulate PDZK1 gene expression in normal skin. Hernando B, Ibarrola Villava M, Oltra Sanchis S, Valcuende-Cavero F, Pitarch G, Mahiques L, Ribas G, Martinez-Cadenas C. Photodermatology Photoimmunology & Photomedicine. 2020 Jan;36(1):70-72. doi: 10.1111/phpp.12508. PMID: 31444921

Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. Perez-Fidalgo J, Grau F, Farinas L, Oaknin A. Critical reviews in oncology/hematology. 2020 Dec 31;158:103209. doi: 10.1016/j.critrevonc.2020.103209. PMID: 33388455

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes Ruiperez A, Chiloiro G, Coco C, Gambacorta M, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rodel C, Rutten H, van de Velde C, Aristei C. Radiotherapy and Oncology. 2020 Jan;142:6-16. doi: 10.1016/j.radonc.2019.07.001. PMID: 31431374

The actual management of colorectal liver metastases. Pérez Santiago L, Dorcaratto D, Garces Albir M, Muñoz Forner E, Huerta Alvaro M, Roselló Keränen S, Sabater Orti L. Minerva Chirurgica. 2020 Oct;75(5):328-344. doi: 10.23736/S0026-4733.20.08436-9. PMID: 32773753

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Bendell J, Sauri T, Cubillo Gracian A, Alvarez R, Lopez-Lopez C, Garcia-Alfonso P, Hussein M, Limon Miron M, Cervantes Ruiperez A, Montagut C, Santos Vivas C, Bessudo A, Plezia P, Moons V, Andel J, Bennouna J, van der Westhuizen A, Samuel L, Rossomanno S, Boetsch C, Lahr A, Franjkovic I, Heil F, Lechner K, Krieter O, Hurwitz H, McCAVE Study Grp. Oncologist. 2020 Mar;25(3):e451-e459. doi: 10.1634/theoncologist.2019-0291. PMID: 32162804

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Gambardella V, Castillo Aliaga J, Tarazona Llavero N, Gimeno Valiente F, Martínez Ciarpaglini M, Cabeza Segura M, Roselló Keränen S, Roda Perez D, Huerta Alvaro M, Cervantes Ruiperez A, Fleitas Kanonnikoff T. Cancer Treatment Reviews. 2020 Jun;86:102015. doi: 10.1016/j.ctrv.2020.102015. PMID: 32248000

Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Sep;31(9):1097-1098. doi: 10.1016/j.annonc.2020.05.030. PMID: 32544547

Unexpected finding of iIntravascular large B-cell lymphoma by a skin biopsy. Guillen-Climent S, Garcia-Vazquez A, Martinez-Ciarpaglini C. Medicina Clinica. 2020 Sep 17;S0025-7753(20)30465-6. doi: 10.1016/j.medcli.2020.04.051. PMID: 32951879

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cáncer. Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE. Breast Cancer Research and Treatment. 2019 Nov;178(1):121-133. doi: 10.1007/s10549-019-05360-3. PMID: 31368034A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cáncer. Cejalvo Andujar J, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes Ruiperez A. Esmo Open. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532. PMID: 31423336

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Pineda B, Diaz-Lagares A, Pérez-Fidalgo JA, Burgués O, González-Barrallo I, Crujeiras AB, Sandoval J, Esteller M, Lluch A, Eroles P. Clinical Epigenetics. 2019 Feb 20;11(1):33. doi: 10.1186/s13148-019-0626-0. PMID: 30786922

Acceleration in the DNA methylation age in breast cancer tumours from very young women. Oltra SS, Peña-Chilet M, Flower K, Martinez MT, Alonso E, Burgues O, Lluch A, Flanagan JM, Ribas G. Scientific Reports. 2019 Oct 18;9(1):14991. doi: 10.1038/s41598-019-51457-6. PMID: 31628391

Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. Ragulan C, Eason K, Fontana E, Nyamundanda G, Tarazona N, Patil Y, Poudel P, Lawlor RT, Del Rio M, Koo SL, Tan WS, Sclafani F, Begum R, Teixeira Mendes LS, Martineau P, Scarpa A, Cervantes A, Tan IB8, Cunningham D, Sadanandam A. Scientific Reports. 2019 May 21;9(1):7665. doi: 10.1038/s41598-019-43492-0. PMID: 31113981

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. Martínez Ciarpaglini M, Fleitas Kanonnikoff T, Gambardella V, Llorca Cardeñosa M, Mongort Sanchis M, Mengual Fenollar R, Nieto G, Navarro Cerveró L, Huerta Alvaro M, Roselló Keränen S, Roda Perez D, Tarazona Llavero N, Navarro Fos S, Ribas Despuig G, Cervantes Ruiperez A. Esmo Open. 2019 May 27;4(3):e000470. doi: 10.1136/esmoopen-2018-000470. PMID: 31231566

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study. Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. Journal of Thoracic Oncology. 2019 Dec;14(12):2120-2132. doi: 10.1016/j.jtho.2019.07.005. PMID: 31349061

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Lancet Oncology. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. PMID: 31003911

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M. Annals of Oncology. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086. PMID: 30860570

Combination of KIR2DS4 and Fc gamma RII alpha polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (vol 9, 2589, 2019). Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Scientific Reports. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z. PMID: 31097738

Combination of KIR2DS4 and Fc gamma RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cáncer. Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Scientific Reports. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. PMID: 30796344

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A. Annals of oncology. 2019 Apr 1;30(4):520-527. doi: 10.1093/annonc/mdz052. PMID: 30796810

CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodríguez ML, Gandhi R, Lafuente-Sanchis A, Aupí M, Alcácer Fernández-Coronado J, Martín-Martorell P, Cremades A, Galbis-Caravajal JM, Alcácer J, Christensen CL, Simms P, Hess A, Asahina H, Kahle MP, Al-Shahrour F, Borgia JA, Lahoz A, Insa A, Juan O, Jänne PA, Wong KK, Carretero J, Shimamura T. Cancer Research. 2019 Sep 1;79(17):4439-4452. doi: 10.1158/0008-5472.CAN-19-0024. PMID: 31273063

Definition of the Rectum: An International, Expert-based Delphi Consensus. DʼSouza N, de Neree Tot Babberich MPM, d’Hoore A, Tiret E, Xynos E, Beets-Tan RGH, Nagtegaal ID, Blomqvist L, Holm T, Glimelius B, Lacy A, Cervantes A, Glynne-Jones R, West NP, Perez RO, Quadros C, Lee KY, Madiba TE, Wexner SD, Garcia-Aguilar J, Sahani D, Moran B, Tekkis P, Rutten HJ, Tanis PJ, Wiggers T, Brown G. Annals of Surgery. 2019 Dec;270(6):955-959. doi: 10.1097/SLA.0000000000003251. PMID: 30973385

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. Lordick F, Obermannova R, Vola D, Douillard J, Mcgregor K, Van Cutsem E, Tabernero J, Ciardiello F, Cervantes Ruiperez A. Esmo Open. 2019 Jul 5;4(3):e000533. doi: 10.1136/esmoopen-2019-000533. PMID: 31354964

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors (vol 24, pg 2517, 2018). Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. Clinical Cancer Research. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. PMID: 30770490

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cáncer. Cardone C, Martinelli E, Troiani T, Sforza V, Avallone A, Nappi A, Montesarchio V, Andreozzi F, Biglietto M, Calabrese F, Bordonaro R, Cordio S, Bregni G, Febbraro A, Garcia-Carbonero R, Feliu J, Cervantes Ruiperez A, Ciardiello F. Esmo Open. 2019 Aug 16;4(4):e000519. doi: 10.1136/esmoopen-2019-000519. PMID: 31555481

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators. Gynecologic Oncology. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. PMID: 30449719

Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis. Martinez-Ciarpaglini C, Machado I, Yoshida A, Nieto G, Berbegall AP, Blanquer-Maceíras MT, Noguera R, Ferrández A, Navarro S. International Journal of Surgical Pathology. 2019 Aug;27(5):568-573. doi: 10.1177/1066896919835945. PMID: 30907195

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. PMID: 30715202

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: 10.1093/annonc/mdz233. PMID: 31378807

Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen. Martinez-Ciarpaglini C, Fernandez-Sellers C, Tarazona N, Roselló S, Huerta M, Roda D, Mongort C, Ferrández A, Navarro S, Cervantes A. Histopathology. 2019 Oct;75(4):517-525. doi: 10.1111/his.13900. PMID: 31081121

In the literature: August 2018. Gambardella V, Bruixola Campos G, Papaccio F, Cejalvo Andujar J, Cervantes Ruiperez A. Esmo Open. 2019 Jul 21;4(4):e000563. doi: 10.1136/esmoopen-2019-000563. PMID: 31423340

In the literature: February 2019. Insa Molla A, Gambardella V, Cervantes Ruiperez A. Esmo Open. 2019 Feb 13;4(1):e000490. doi: 10.1136/esmoopen-2019-000490. PMID: 30962957

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. Martinez-Ciarpaglini C, Oltra S, Roselló S, Roda D, Mongort C, Carrasco F, Gonzalez J, Santonja F, Tarazona N, Huerta M, Espí A, Ribas G, Ferrández A, Navarro S, Cervantes A. Modern Pathology. 2019 Feb;32(2):306-313. doi: 10.1038/s41379-018-0124-5. PMID: 30206410

MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. Pellegrini C, Botta F, Massi D, Martorelli C, Facchetti F, Gandini S, Maisonneuve P, Avril M, Demenais F, Bressac-de Paillerets B, Hoiom V, Cust A, Anton-Culver H, Gruber S, Gallagher R, Marrett L, Zanetti R, Dwyer T, Thomas N, Begg C, Berwick M, Puig S, Potrony M, Nagore E, Ghiorzo P, Menin C, Manganoni A, Rodolfo M, Brugnara S, Passoni E, Sekulovic L, Baldini F, Guida G, Stratigos A, Ozdemir F, Ayala F, Fernandez-de-Misa R, Quaglino P, RIBAS DESPUIG G, Romanini A, Migliano E, Stanganelli I, Kanetsky P, Pizzichetta M, García-Borrón J, Nan H, Landi M, Little J, Newton-Bishop J, Sera F, Fargnoli M, Raimondi S, IMI Study Group, GEM Study Group, M-SKIP Study Group. Lancet Child & Adolescent Health. 2019 May;3(5):332-342. doi: 10.1016/S2352-4642(19)30005-7. PMID: 30872112

miR302a and 122 are deregulated in small extracellular vesicles from ARPE-19 cells cultured with H2O2. Oltra M, Vidal-Gil L, Maisto R, Oltra SS, Romero FJ, Sancho-Pelluz J, Barcia JM. Scientific Reports. 2019 Nov 29;9(1):17954. doi: 10.1038/s41598-019-54373-x. PMID: 31784665

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. Fleitas-Kanonnikoff T, Martinez-Ciarpaglini C, Ayala J, Gauna C, Denis R, Yoffe I, Sforza S, Martínez MT, Pomata A, Ibarrola-Villava M, Arevshatyan S, Burriel V, Boscá D, Pastor O, Ferrer-Martinez A, Carrasco F, Mongort C, Navarro S, Ribas G, Cervantes A. Cancer Medicine. 2019 Jun;8(6):3120-3130. doi: 10.1002/cam4.2191. PMID: 31059199

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J. Clinical Cancer Research. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. PMID: 31088831

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer. Gambardella V, Gimeno-Valiente F, Tarazona N, Martinez-Ciarpaglini C, Roda D, Fleitas T, Tolosa P, Cejalvo JM, Huerta M, Roselló S, Castillo J, Cervantes A. Clinical Cancer Research. 2019 Mar 1;25(5):1639-1649. doi: 10.1158/1078-0432.CCR-18-242. PMID: 30504425

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Adamo B, Bellet M, Paré L, Pascual T, Vidal M, Pérez Fidalgo JA, Blanch S, Martinez N, Murillo L, Gómez-Pardo P, López-González A, Amillano K, Canes J, Galván P, González-Farré B, González X, Villagrasa P, Ciruelos E, Prat A. Breast Cancer Research. 2019 Sep 18;21(1):108. doi: 10.1186/s13058-019-1195-z. PMID: 31533777

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). Isla D, De Las Peñas R, Insa A, Marsé R, Martínez-Banaclocha N, Mut P, Morán T, Sala MÁ, Massuti B, Ortega AL, Jurado JM, Gómez-Codina J, Diz P, Artal Á, Gutiérrez V, Vázquez MF, Viñolas N, Maestu I, Camps C, Álvarez R, de Mon Soto MÁ, Ponce S, Provencio M. Lung Cancer. 2019 Sep;135:161-168. doi: 10.1016/j.lungcan.2018.11.041. PMID: 31446990

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cáncer. Argilés G, André T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J. European Journal of Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. PMID: 30889492

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Clinical Cancer Research. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740.PMID: 30770348

Preclinical models for precision oncology (vol 1870, pg 239, 2018). Ibarrola-Villava M, Cervantes A, Bardelli A. Biochimica et Biophysica Acta-Reviews on Cancer. 2019 Dec;1872(2):188292. doi: 10.1016/j.bbcan.2019.05.002. PMID: 31138435

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. Baguena G1, Pellino G1, Frasson M1, Roselló S2, Cervantes A2, García-Granero A1, Giner F3, García-Granero E. Diseases of the Colon & Rectum. 2019 Jun;62(6):684-693. doi: 10.1097/DCR.0000000000001367. PMID: 30839315

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Ducreux M, Petersen LN, Öhler L, Bergamo F, Metges JP, de Groot JW, Wang JY, García Paredes B, Dochy E, Fiala-Buskies S, Cervantes A, O’Connor JM, Falcone A; CORRELATE Investigators. European Journal of Cancer. 2019 Dec;123:146-154. doi: 10.1016/j.ejca.2019.09.015. PMID: 31698328

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. Journal of Thoracic Oncology. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. PMID: 30978502

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M. Clinical & Translational Oncology. 2019 Jan;21(1):3-17. doi: 10.1007/s12094-018-1978-1. PMID: 30446985

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A. Annals of Oncology. 2019 Nov 1;30(11):1804-1812. doi: 10.1093/annonc/mdz390. PMID: 31562764

The Medical Oncology resident mentor: situation and workload. Elez E, Quintanar T, Bosch-Barrera J, Corral J, Lainez N, Moreno V, Rodriguez CA, Gonzalez-Flores E, Cervantes A. Clinical & Translational Oncology. 2019 Mar;21(3):304-313. doi: 10.1007/s12094-018-1923-3. PMID: 30062521

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma. Gambardella V, Fleitas T, Tarazona N, Cejalvo JM, Gimeno-Valiente F, Martinez-Ciarpaglini C, Huerta M, Roselló S, Castillo J, Roda D, Cervantes A. Annals of Oncology. 2019 Aug 1;30(8):1254-1264. doi: 10.1093/annonc/mdz143. PMID: 31046106

Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cáncer. Forés-Martos J, Catalá-López F, Sánchez-Valle J, Ibáñez K, Tejero H, Palma-Gudiel H, Climent J, Pancaldi V, Fañanás L, Arango C, Parellada M, Baudot A, Vogt D, Rubenstein JL, Valencia A, Tabarés-Seisdedos R. Molecular Autism. 2019 Apr 8;10:17. doi: 10.1186/s13229-019-0262-8. PMID: 31007884

Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cáncer. Gambardella V, Fleitas T, Cervantes A. Annals of Oncology. 2019 Mar 1;30(3):351-352. doi: 10.1093/annonc/mdz008. PMID: 30657856

Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations. Roda D, Roselló S, Cervantes A. Annals of Oncology. 2019 Sep 1;30(9):1409-1410. doi: 10.1093/annonc/mdz229. PMID: 31350557

ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. Gimeno-Valiente F, Riffo-Campos ÁL, Vallet-Sánchez A, Siscar-Lewin S, Gambardella V, Tarazona N, Cervantes A, Franco L, Castillo J, López-Rodas G. Scientific Reports. 2019 Jun 27;9(1):9339. doi: 10.1038/s41598-019-45411-9. PMID: 31249328

Proyectos
Referencia: ICI20/00009
Título: Investigación Clínica Independiente
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2021 – 2024
Presupuesto: 1.039.970 €Referencia: PT20/00100
Título: Plataforma de Investigación Clínica
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2021 – 2023
Presupuesto: 199.650 €Referencia: REBECCA
Título: REsearch on BrEast Cancer induced chronic conditions supported by Causal Analysis of multi-source data
Entidad Financiadora: European Commission
Investigador principal: Cristina Hernando Meliá
Duración: 2021 –
Presupuesto: Referencia: GV/2020/189
Título: Estudio de la carga tumoral ganglionar y el budding tumoral como factores pronósticos el cáncer colorrectal en estadios localizados
Entidad Financiadora: Conselleria de Educación Cultura y Deporte
Investigador principal: Mª Carolina Martínez Ciarpaglini
Duración: 2020 – 2021
Presupuesto: 16.000 €Referencia: 825832 – LEGACy
Título: CeLac and European consortium for a personalized medicine approach to Gastric Cancer
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2019 – 2022
Presupuesto: €3.577.431,27 (INCLIVA: €638.315)Referencia: PI18/01508
Título: Macrófagos asociados al tumor, angiogénesis tumoral y resistencia a las terapias en Cáncer Gástrico Difuso fenotipo Mesenquimal
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Tania Carolina Fleitas Kanonnikoff
Duración: 2019 – 2021
Presupuesto: 99.220 €Referencia: PI18/01909
Título: Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Andrés Cervantes Ruipérez, Desamparados Roda
Duración: 2019 – 2021
Presupuesto: 141.570 €Referencia: PT17/0017/0003
Título: Clinical Research and Trials Platform
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2018 – 2021
Presupuesto: 266.475 €Referencia: CB16/12/00473
Título: CIBER Oncología
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2017 –
Presupuesto: Referencia: AC15/00096
Título: Evolution of resistant clones to novel target-directed drugs in colorectal tumours. A genetic and apigenetic study of intratumoral herterogeneity dynamics
Entidad Financiadora: European Commission (Programación conjunta internacional ISCIII)
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2016 – 2020
Presupuesto: 29.645 €
+ Información

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M. Clinical & Translational Oncology. 2019 Jan;21(1):3-17. doi: 10.1007/s12094-018-1978-1. PMID: 30446985

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. PMID: 30715202

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: 10.1093/annonc/mdz233. PMID: 31378807

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

Título: Study of the epi-/genomic dysregulation of breast cancer in women under 35 years and evaluation of cellular models
Doctorando: Oltra Sanchis, Sara
Director: Ribas Despuig, Gloria; Lluch Hernández, Ana
Fecha: 18/01/2019
Universidad: Universitat de ValènciaTítulo: Genetic determinants of atr inhibitor sensitivity and resistance in gastric cancer
Doctorando: Llorca Cardeñosa, Marta Jessica
Director: Cervantes Ruipérez, Andrés; Ribas Despuig, Gloria
Fecha: 22/07/2019
Universidad: Universitat de ValènciaTítulo: A multi-omic liquid biopsy-based signature as a valuable tool to assess minimal residual disease in localised colorectal cancer
Doctorando: Tarazona Llavero, Noelia
Director: Cervantes Ruipérez, Andrés
Fecha: 23/07/2019
Universidad: Universitat de ValènciaTítulo: Role of EDPR1 and the ZNF518B factor in the development of colorectal cancer
Doctorando: Gimeno Valiente, Francisco
Director: Castillo Aliaga, Josefa; López Rodas, Gerardo; Franco Vera Luis
Fecha: 03/12/2019
Universidad: Universitat de València